3CL Protease Inhibitors: In Vitro Data for Tollovid®

Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, announced that its majority-owned subsidiary 3CL Pharma, Ltd. announced that its mechanism-based 3CL protease inhibitors Tollovir® and Tollovid™ that target the active site of the 3CL protease showed robust inhibitory activity against the 3CL protease of the BA.1 and BA.2 strains of the Omicron SARS-CoV-2 variant of concern (VOC). Additionally, Tollovir and Tollovid showed inhibitory activity against the original wild-type SARS-CoV-2 strain, as well as the Alpha, Beta, Delta and Gamma VOCs. The results showed IC50 binding affinity of <5 for Tollovid and <1 for Tollovir for each of the different SARS-CoV-2 strains. The experiments were completed at Tel Aviv University in Israel.